CIA
TTNP

Cape Investment Advisory’s Titan Pharmaceuticals TTNP Stock Holding History

Cape Investment Advisory’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$4 – 1174
2025
Q2 		$4 Hold
1
– – ﹤0.01% 1170
2025
Q1 		$4 Hold
1
– – ﹤0.01% 1135
2024
Q4 		$3 Hold
1
– – ﹤0.01% 1140
2024
Q3 		$5 Hold
1
– – ﹤0.01% 956
2024
Q2 		$6 Hold
1
– – ﹤0.01% 927
2024
Q1 		$7 Buy
+1
New +$7 ﹤0.01% 932
2023
Q4 		– Hold
0
– – – 1210
2023
Q3 		– Hold
0
– – – 945
2023
Q2 		– Hold
0
– – – 911
2023
Q1 		– Hold
0
– – – 962

Other funds holding TTNP

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cape Investment Advisory's TTNP Position: Q3 2025 in Review

Cape Investment Advisory sold out of Titan Pharmaceuticals (TTNP) in Q3 2025, closing a stake of 1 share — an estimated $4 sold.

Cape Investment Advisory first reported a position in TTNP in Q1 2024 and held it in 6 quarters. The position peaked at $7 in Q1 2024. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2025.

  • Cape Investment Advisory reported no remaining Titan Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cape Investment Advisory sold 1 Titan Pharmaceuticals share in Q3 2025, an estimated $4.
  • Cape Investment Advisory first reported a position in Titan Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Cape Investment Advisory's Titan Pharmaceuticals position peaked at $7 in Q1 2024.
  • 18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2025.

Based on Cape Investment Advisory's 13F filing for Q3 2025, filed 29 Dec 2025.